1991
DOI: 10.1016/0092-8674(91)90499-o
|View full text |Cite
|
Sign up to set email alerts
|

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

37
1,315
4
7

Year Published

1996
1996
2007
2007

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 1,965 publications
(1,363 citation statements)
references
References 34 publications
37
1,315
4
7
Order By: Relevance
“…Analysis of the tumor suppressing potential of the Tg737 gene in a mouse liver tumorigenic cell line The pBAP737-neo vector was constructed by removal of the human b actin-Tg737 cDNA-SV40 polyA fragment (containing position 1 ± 2545 and 5' untranslated region of the Tg737 cDNA) by ClaI digestion from the vector pBAP737 (Moyer et al, 1994) and placed into the ClaI site of the pPGK-neo vector (Soriano et al, 1991). Expression of the Tg737 gene was accomplished by introducing the pBAP737-neo and pPGK-neo control vector into the HL617-1T1 mouse oval cell line (Richards et al, 1996(Richards et al, , 1997 utilizing Lipofectamine technology (GIBCO/BRL).…”
Section: Methodsmentioning
confidence: 99%
“…Analysis of the tumor suppressing potential of the Tg737 gene in a mouse liver tumorigenic cell line The pBAP737-neo vector was constructed by removal of the human b actin-Tg737 cDNA-SV40 polyA fragment (containing position 1 ± 2545 and 5' untranslated region of the Tg737 cDNA) by ClaI digestion from the vector pBAP737 (Moyer et al, 1994) and placed into the ClaI site of the pPGK-neo vector (Soriano et al, 1991). Expression of the Tg737 gene was accomplished by introducing the pBAP737-neo and pPGK-neo control vector into the HL617-1T1 mouse oval cell line (Richards et al, 1996(Richards et al, , 1997 utilizing Lipofectamine technology (GIBCO/BRL).…”
Section: Methodsmentioning
confidence: 99%
“…While these data appear to provide an explanation for most of the di erences between published reports, Broome and Hunter (1996) demonstrated a requirement for Src family kinases in growth factor signaling in cells expressing various dominant negative forms of Src. The starting cell line used (Src 7/7 ) was originally made using largeT (Soriano et al, 1991). While this is di cult to reconcile with the data presented here, we note that for these experiments the cells were selected using G418, even though the Src 7/7 cells were originally both largeT expressing and G418 resistant.…”
mentioning
confidence: 86%
“…A 5.5-kb HindIII/AseI genomic fragment containing the catalytic domain and an upstream region (exons 17-20) was then inserted on the other side of the loxP site. Separately, a pBluescript II SK-based plasmid was generated such that it contained a loxP site next to a neomycin resistance cassette under the control of the phosphoglycerate kinase 1 gene promoter (pgk-neo cassette; Soriano et al, 1991) with the pgk-neo cassette being flanked by frt sites (Possemato et al, 2002).…”
Section: Construction Of the Dnmt3a Targeting Constructmentioning
confidence: 99%